LBA76 Overall survival (OS) results from the phase III TROPiCS-02 study of sacituzumab govitecan (SG) vs treatment of physician's choice (TPC) in patients (pts) with HR+/HER2- metastatic breast cancer (mBC)

Hope S. Rugo; A. Bardia; F. Marmé; J. Cortés; P. Schmid; D. Loirat; Olivier Trédan; E.M. Ciruelos; F. Dalenc; P. Gomez Pardo; K. Jhaveri; R.J. Delaney; T. Valdez; H. Wang; W. Verret; S.M. Tolaney

doi:10.1016/j.annonc.2022.08.012

LBA76 Overall survival (OS) results from the phase III TROPiCS-02 study of sacituzumab govitecan (SG) vs treatment of physician's choice (TPC) in patients (pts) with HR+/HER2- metastatic breast cancer (mBC)

Hope S. Rugo(University of California, San Francisco), A. Bardia(Harvard University), F. Marmé(Heidelberg University), J. Cortés(Universidad Europea de Madrid), P. Schmid(Queen Mary University of London), D. Loirat(Institut Curie), Olivier Trédan(Centre Léon Bérard), E.M. Ciruelos(Hospital Universitario 12 De Octubre), F. Dalenc(Institut Claudius Regaud), P. Gomez Pardo(Vall d'Hebron Hospital Universitari), K. Jhaveri(Memorial Sloan Kettering Cancer Center), R.J. Delaney(Gilead Sciences (United States)), T. Valdez(Gilead Sciences (United States)), H. Wang(Gilead Sciences (United States)), W. Verret(Gilead Sciences (United States)), S.M. Tolaney(Harvard University)

Annals of Oncology

September 1, 2022

10.1016/j.annonc.2022.08.012

Cited by 56Open Access

Full Text

Abstract

Related Papers

No related papers found

Powered by citation graph analysis